Spring til hovednavigation
Spring til søgning
Spring til hovedindhold
Aarhus Universitet Forside
Hjælp og OSS
English
Dansk
Forside
Profiler
Forskningsenheder
Projekter
Publikation
Priser
Aktiviteter
Kurser
Presse/medier
Søg efter ekspertise, navn eller tilknytning
Mette Holm
Klinisk lektor
,
Institut for Klinisk Medicin - Børn og Unge
Fastnet
+4578451520, +4530715334
E-mail
mette.holm
clin.au
dk
Palle Juul-Jensens Boulevard 103
,
1242, 264
8200
Aarhus N
Danmark
2006
2024
Publikationer pr. år
Vis
Fingeraftryk
Netværk
Publikation
(36)
Aktiviteter
(3)
Lignende profiler
(6)
Fingeraftryk
Dyk ned i forskningsemnerne, hvor Mette Holm er aktive. Disse emneetiketter kommer fra dennes persons arbejder. Sammen danner de et unikt fingerprint.
Sorter
Vægt
Alfabetisk
Medicine and Dentistry
Cohort Analysis
100%
Adolescent
88%
Severe Acute Respiratory Syndrome Coronavirus 2
77%
Disease
76%
Infection
69%
Serositis
66%
COVID-19
64%
Bone and Joint Infections
44%
Tuberculosis
33%
Symptom
33%
Diagnosis
33%
Antiinfective Agent
29%
Antibiotics
24%
Attributable Risk
23%
Transverse Myelitis
22%
Staphylococcal Bacteremia
22%
Postcovid Syndrome
22%
Artificial Respiration
22%
Omicron Coronavirus Variant
22%
Human Respiratory Syncytial Virus
22%
IPEX Syndrome
22%
Hypereosinophilic Syndrome
22%
Panton Valentine Leukocidin
22%
Enterovirus D68
22%
COVID-19 Vaccination
22%
Group A Streptococcal Infection
22%
Proteomics
22%
Noninferiority Trial
22%
Adolescence
22%
Mycoplasma Pneumonia
22%
Patient Referral
16%
Intensive Care
12%
Prophylaxis
11%
Childhood Tuberculosis
11%
Latent Tuberculosis
11%
Pediatrics
9%
Intensive Care Unit
8%
Sequela
6%
Exanthem
6%
Mucositis
6%
Mass Screening
5%
Prodrome
5%
Deterioration
5%
Interferon Gamma Release Assay
5%
Health Assessment
5%
Fatality
5%
Awareness
5%
Antitoxin
5%
Staphylococcus Aureus
5%
Bacteremia
5%
Pharmacology, Toxicology and Pharmaceutical Science
SARS Coronavirus
88%
Cohort Study
67%
Infection
55%
Vaccination Policy
44%
Inflammation
44%
Disease
30%
Pandemic
27%
Delta Variant
22%
Staphylococcal Bacteremia
22%
Myelitis
22%
Panton-Valentine Leukocidin
22%
Symptom
22%
Prospective Cohort Study
22%
Group A Streptococcal Infection
22%
Bone and Joint Infections
22%
Antibiotic Agent
22%
Noninferiority Trial
22%
Mycoplasma Pneumonia
22%
Mucosa Inflammation
11%
Rash
11%
Antiinfective Agent
7%
Superinfection
5%
Osteomyelitis
5%
Soft Tissue Infection
5%
Pleura Empyema
5%
Necrotizing Fasciitis
5%
Herpes Zoster
5%
Bacterial Arthritis
5%
Toxic Shock Syndrome
5%
Meningitis
5%
Fatality
5%
Staphylococcus Aureus
5%
Deterioration
5%
Bacteremia
5%
Antitoxin
5%
Effusion
5%
Upper Respiratory Tract Infection
5%
Bacterial Infection
5%
Infectious Agent
5%
Muscle Weakness
5%
Immunology and Microbiology
Human Immunodeficiency Virus 1
66%
COVID-19
44%
T Cell Receptor
34%
Immune System
25%
Immune Response
25%
Infectious Disease
22%
Omicron Coronavirus Variant
22%
Herpesviridae
22%
Human Immunodeficiency Virus
22%
Transcription Factor GATA 2
22%
Hematopoietic Cell
22%
Cell Transplantation
22%
Adolescence
22%
Mycoplasma pneumoniae
22%
T-Helper Cell
11%
Severe Acute Respiratory Syndrome Coronavirus 2
11%
Clinical Microbiology
11%
Immunodeficiency
11%
Leadership
11%
CD4 Lymphocyte Count
8%
Sirolimus
7%
Viral Load
6%
Inflammation Response
5%
T Cell
5%
Mycobacteria
5%
Myeloid
5%
